Alia Therapeutics
9.5.2023 10:11:23 CEST | ACCESS Newswire | Press release
MILAN, ITALY / ACCESSWIRE / May 9, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Adel Nada as an independent member of the Board of Directors.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Adel Nada is Co-founder and Chief Executive Officer of GentiBio, a biotherapeutics company that is developing engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics, where he worked on advancing engineered regulatory T cell therapeutics.
Over the past 15 years, he has successfully led translational and immunology programs for experimental and approved therapies, spanning small and large molecules, as well as engineered immune cell products.
Paola Pozzi, Partner at Sofinnova Partners and a member of Alia's Board of Directors, said: "Adel's experience and knowledge of the field will help guide Alia towards the next stage in its development. We feel very fortunate to have such an esteemed leader join our Board of Directors."
Adel Nada, Independent Board Director of Alia, said: "I'm delighted to have been invited to join the board of such a compelling biotech with a very differentiated genome editing platform. I look forward to advancing Alia's platforms and pipeline to enable novel, tailored gene editing strategies that have the potential to overcome current limitations of genome editing and bring more therapies to patients with underserved and currently untreatable diseases and conditions."
Letizia Goretti, Chief Executive Officer of Alia, said: "Adel's experience in biotech is both broad and deep. We are really excited to partner with him as Alia's growth accelerates."
Adel received his medical degree from Alexandria University in Egypt and his master's degree in clinical research from the Pharmacology Dept. at Rush University in Chicago, where he also held an academic position and practiced for 10 years in affiliated hospitals.
About Alia Therapeutics
Alia Therapeutics is an Italian biotech start-up whose mission is to develop innovative treatments for incurable genetic diseases using gene editing technology. The company was founded in October 2018 by Anna Cereseto and a group of researchers from CIBIO, the biotech department of the University of Trento, who discovered the core CRISPR technologies exploited by the start-up. Read more at aliatherapeutics.com
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
For more information about Sofinnova Telethon, visit https://sofinnovapartners.com/strategy/telethon
Contact
Letizia Goretti
CEO, Alia Therapeutics
info@aliatx.com
SOURCE: Alia Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/753506/Alia-Therapeutics-appoints-Adel-Nada-as-Independent-Board-Director
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra Receives 2026 Eaton Supplier Excellence Award3.9.2026 16:45:00 CEST | Press release
Recognition places Formerra among several dozen honorees from a supplier network of more than 30,000. ROMEOVILLE, IL / ACCESS Newswire / September 3, 2026 / Formerra, a leader in performance materials distribution, was recognized for its partnership at Eaton's 2026 Global Supplier Conference & Excellence Awards, held Thursday, August 27 in Beachwood, Ohio. Formerra was one of only 30 suppliers recognized with Eaton's Supplier Excellence Award from among the company's global network of more than 30,000 supplier partners. Eaton grants the Supplier Excellence Award to suppliers that exceed expectations through exceptional performance, innovation, and contributions to growth. Formerra serves as Eaton's preferred plastics distribution partner, a role built through disciplined execution and engagement across Eaton's corporate organization and manufacturing sites. While the partnership began over 15 years ago in North America, it now extends into Asia, Europe, and the Middle East, where Forme
DistillerSR Joins European MedTech Consortium to Digitalize Medical Device and IVD Conformity Assessments3.9.2026 16:00:00 CEST | Press release
€4 million European-funded DIGICAP project brings together 19 organizations to replace document-based conformity assessments with machine-readable data. DistillerSR named one of five technology providers building the framework. OTTAWA, ON / ACCESS Newswire / September 3, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced its participation in DIGICAP (DIGItalisation of the Conformity Assessment Process), a €4 million European initiative uniting 19 organizations across 12 EU countries to digitalize how medical devices and in vitro diagnostics are certified for the European market. The project is funded under Horizon Europe, the world's largest multinational research and innovation program, with a budget of €95.5 billion for the 2021-2027 period. DistillerSR is one of five regulatory technology providers selected to support the project, alongside Veeva, MEDDEVO, AUREVIA and Hardian Health. The company will work in the
U.S. Polo Assn. Marks Continued Success as Title Sponsor of the 2026 Pacific Coast Open3.9.2026 13:00:00 CEST | Press release
Historic Championship Brings Together Elite Competition, California Lifestyle, and the Authentic Spirit of the Sport of Polo SANTA BARBARA, CA / ACCESS Newswire / September 3, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), celebrated the conclusion of the 2026 U.S. Polo Assn. Pacific Coast Open, held August 14-30 at the renowned Santa Barbara Polo & Racquet Club in Carpinteria, California. As one of the oldest polo tournaments in the world and the most prestigious championship in the Western United States, the Pacific Coast Open once again delivered world-class competition while highlighting the enduring connection between sport, style, and community. 2026 U.S. Polo Assn. Pacific Coast Open Winners, Klentner Ranch, on stage with trophy; Photo Credit: Michelle Lauren This year marked the second time U.S. Polo Assn. served as Title Sponsor of the Pacific Coast Open and the ninth consecutive year partnering with the Santa Barbara Polo & Ra
CubeLogic Launches a New Generation of Credit Risk Technology with RiskCubed Version 123.9.2026 11:00:00 CEST | Press release
The most significant technology shift in CubeLogic's history - delivering real-time performance, natural language reporting, and AI built directly into the platform. LONDON, UK / ACCESS Newswire / September 3, 2026 / CubeLogic, the leading provider of enterprise risk and compliance software for trading organisations across the energy and commodities sector, today launched Version 12 (V12) of its RiskCubed platform - bringing real-time, AI-powered credit risk management to a market that has long depended on overnight processing. Built on modern, cloud-native foundations, V12 re-architects how RiskCubed stores data, delivers reporting, runs margining and scales to meet demand. For credit teams, that changes the working day as well as the technology behind it: exposure positions can be reviewed as they update rather than waiting on a batch, and reports that previously required a specialist can be built in the moment. "We are excited to partner with our clients in developing the next gener
Eudia and Harbor Partner to Accelerate AI Transformation for Enterprise Legal Teams1.9.2026 20:25:00 CEST | Press release
Harbor's trained industry experts will deliver advisory, implementation, training, and adoption enablement, helping enterprise legal departments deploy Eudia's augmented intelligence platform successfully at scale PALO ALTO, CA / ACCESS Newswire / September 1, 2026 / Eudia, the augmented intelligence platform for legal, contracting, and compliance work across the enterprise, today announced a strategic partnership with Harbor, the leading provider of professional and technology services to the legal industry. Harbor's industry experts, who guide digital transformation for close to 600 corporate law departments and more than 80% of Global 200 law firms, will help enterprise legal teams adopt Eudia's platform and deploy it successfully at scale. Enterprise legal departments are under growing pressure to show results from AI. The challenge is rarely the technology alone: institutional knowledge sits scattered across contracts, policies, and a small number of experienced professionals, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom